Tarsus Pharmaceuticals, Inc. · NASDAQ:TARS
Tarsus Pharmaceuticals — Investor Presentation (April 2021)
28 slides from Tarsus Pharmaceuticals's investor presentation, Apr 9, 2021
Slide 1: Tarsus Corporate Presentation
April 2021 Tarsus Corporate Presentation © Tarsus Pharmaceuticals 2021 Exhibit 99.1
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation contains forward-looking statements that involve risks and uncertainties. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current expectations and projections about future events and finan
Slide 3: Corporate Highlights
Corporate Highlights Potential for first-ever FDA-approved therapeutic for Demodex blepharitis. Significant market opportunity with no approved therapies Pivotal clinical trials in 2021: Saturn-1 Phase 2b/3 enrollment complete and top line data expected in Summer, Saturn-2 Phase 3 initiation planned
Slide 4: Tarsus Executive Leadership Team
Tarsus Executive Leadership Team Bobby Azamian, M.D., Ph.D., President & CEO, Co-Founder Former CEO/CMO Metavention Extensive investment/entrepreneurial experience with Versant and Third Rock Ventures Medicine at Brigham, M.D., Harvard, Ph.D. Chemistry, Oxford Michael Ackermann, Ph.D., Chairman, Co-
Slide 5: Our Mission
Our Mission © Tarsus Pharmaceuticals 2021 Focusing on unmet needs, we apply proven science and new technology to revolutionize treatment for patients, starting with eye care. Our Mission A future in which patient needs are met through boundless therapeutic ingenuity. Our Vision
Slide 6: Blepharitis Is a Large and Underserved Market in Eye Care
Blepharitis Is a Large and Underserved Market in Eye Care Large Patient Population with Significant Disease Impact Titan (collarette clinic prevalence) and Atlas (disease impact) studies demonstrate high prevalence of disease and significant burden on patients Significant Head Start on Diagnosis 2.1
Slide 7: Blepharitis has Potential Similarities to Dry Eye Market Years Ago
Blepharitis has Potential Similarities to Dry Eye Market 15 Years Ago Potential Large Latent Demand for a New Therapy Large untapped patient population that was activated through education of ECPs and patients In 2003, no approved dry eye therapeutics With approval of a prescription therapeutic and
Slide 8: Collarettes Are Pathognomonic Sign of Demodex Infestation
Collarettes Are Pathognomonic Sign of Demodex Infestation Collarettes Are Composed of Mite Waste Products and Eggs1 Regurgitated undigested material combined with epithelial cells, keratin, and mite eggs Contain digestive enzymes, which cause irritation Easily and Rapidly Diagnosed with Standard Eye
Slide 9: Titan Study Confirms Widespread Collarette Prevalence
© Tarsus Pharmaceuticals 2021 Titan Study Confirms Widespread Collarette Prevalence in ECP Clinic Patients and Key Patient Segments Study Overview Key Findings IRB-APPROVED RETROSPECTIVE CHART REVIEW Examined presence of collarettes and other characteristics LARGE-SCALE ALL-COMERS (1,032 patients) C
Slide 10: Atlas Study Reveals Symptomatic and Psychosocial Burden of Demodex Blepharitis
Atlas Study Reveals Symptomatic and Psychosocial Burden of Demodex Blepharitis © Tarsus Pharmaceuticals 2021 Multicenter, observational study of patients pre-screened for the Saturn-1 pivotal trial Evaluated the clinical and patient reported impact of Demodex blepharitis (interim analysis of 311 pat
Slide 11: TP-03 is Designed to Eradicate Demodex Mites and Treat Demodex Blepharitis
© Tarsus Pharmaceuticals 2021 TP-03 is Designed to Eradicate Demodex Mites and Treat Demodex Blepharitis
Slide 12: TP-03 is a Novel Therapeutic Designed to Eradicate Demodex Mites
TP-03 is a Novel Therapeutic Designed to Eradicate Demodex Mites and Treat Demodex Blepharitis TP-03 is designed to paralyze the mite nervous system through parasite-specific GABA inhibition Lotilaner Potent non-competitive antagonist of insect and arachnid GABA-Cl channels Highly lipophilic molecul
Slide 13: TP-03 Is a Novel Drug Designed to Treat Demodex Blepharitis
Product Form Multi-dose eye drop solution bottle, preserved Targeted Use Treatment of Demodex blepharitis MOA Paralysis and death of Demodex mites Diagnosis Collarettes identified in standard eye examination Dosing BID* for 6 weeks Efficacy Goal 1o collarette cure rate, 2o mite eradication, 2o redne
Slide 14: Trial / Study Design, Endpoints and Results Achieved
Trial / Study Design Endpoints Results Achieved Status PoC: Mercury Ex-vivo mite testing on 80 mites Ex-vivo mite death count 100% mites dead within 24 hours (p < 0.001) Clinical Trials Collarette Cure Rate** Mite Eradication Rate P2a: Mars* 28-day BID dosing, single arm (n=15) Pilot formulation Col
Slide 15: Baseline Cure of Collarettes with BID Use of TP-03
Baseline Cure of Collarettes with BID Use of TP-03 Post Treatment © Tarsus Pharmaceuticals 2021
Slide 16: Europa Phase 2b: Efficacy Endpoints of Collarette Cure Rate and Mite Eradication Rate Both Achieved
Europa Phase 2b: Efficacy Endpoints of Collarette Cure Rate and Mite Eradication Rate Both Achieved Primary and secondary efficacy endpoints same as Saturn-1 trial Collarette Cure (0-2 collarettes)* Mite Eradication (0 mites) © Tarsus Pharmaceuticals 2021 * The primary efficacy endpoint was the prop
Slide 17: Europa Phase 2b: Statistically Significant Composite Cure Rate
Europa Phase 2b: Statistically Significant Composite Cure Rate Lid erythema cure + collarette cure, additional secondary endpoint Composite Cure (Erythema Cure + Collarette Cure) © Tarsus Pharmaceuticals 2021 Erythema + Collarette Cure (Analysis Eye) (N=22,20) (N=23,20) (N=18,18) (N=15,19)
Slide 18: TP-03 Clinical Data Show Recurrence Rate Post-Treatment
TP-03 Phase 2 Clinical Data Show Recurrence Rate of Clinical-Grade Demodex Blepharitis Post-Treatment >10 Collarettes on Lid Mite Density of 1.0 or More © Tarsus Pharmaceuticals 2021 Data account for presence of collarettes or mites on either eye, (upper eyelid for collarette score) Post treatment d
Slide 19: Elevate eyelid health as a foundation of ocular wellness
Elevate eyelid health as a foundation of ocular wellness Educate on the importance, prevalence and impact of Demodex blepharitis, and how disease management can be part of the overall practice routine Build a strong scientific platform through KOL engagement, evidence generation, and data disseminat
Slide 20: Market Research Shows Positive Reaction from Providers and Patients
Market Research Shows Positive Reaction from Providers and Patients After exposure to information on collarettes, Demodex blepharitis and TP-03 Phase 2 data Clinician Intent to Prescribe Patient Intent to Seek a Doctor N = 50 eye care providers (25 MDs, 25 ODs) Market research sponsored by Tarsus N
Slide 21: Payers view the potential profile of TP-03 as having a strong value proposition
Payers view the potential profile of TP-03 as having a strong value proposition Objective clinical outcomes and targeted mechanism of action contribute to positive payer feedback Payers acknowledge the clinical relevance of both collarette cure and mite eradication No current Rx treatments available
Slide 22: License for TP-03 in Greater China Expands Market and Provides Non-Dilutive Funding
LianBio was founded by Perceptive Advisors, and is focused on developing and accelerating availability of paradigm-shifting medicines to patients in China and major Asian markets LianBio to provide Tarsus up to $200 million in milestones and other proceeds: $70 million expected over the next 12 mont
Slide 23: Pipeline with Different Formulations of Novel API
Pipeline with Different Formulations of Novel API Anticipated clinical trial events in our programs in 2021 (and selected events beyond) * Anticipated milestones are subject to the impact of the ongoing COVID-19 pandemic on our business and those of our partners. ** We intend to rely on preclinical
Slide 24: TP-03 Eye Drop: Potential Label Expansion Opportunity in Meibomian Gland Disease
TP-03 Eye Drop: Potential Label Expansion Opportunity in Meibomian Gland Disease Potential label expansion into Meibomian Gland Disease MGD is a primary cause of Dry Eye; MGD has been found to be approximately two-thirds of the estimated 34 million Dry Eye patient population in the United States TP-
Slide 25: TP-04 Topical Potential New Treatment for Rosacea
TP-04 Topical Potential New Treatment for Rosacea *Intend to leverage systemic preclinical data from our TP-03 program and augment with additional dermal preclinical studies to select formulation in order to advance to Phase 1/2, which we intend to conduct outside the United States. We may need to a
Slide 26: TP-05 Oral Tablet: Long-Acting Endectocide for Lyme Disease Prevention
TP-05 Oral Tablet: Long-Acting Endectocide for Lyme Disease Prevention Lyme Disease Prevention Represents a Significant Unmet Need Lyme Disease: Over 300k US cases/year Bacterial infection carried by ticks >30M people in US at risk of exposure ~20M in high incidence geographies Previous vaccine, LYM
Slide 27: Tarsus Summary
Tarsus Summary TP-03 is a novel therapeutic with potential to be the first FDA-approved therapeutic and the standard of care for the treatment of Demodex blepharitis Clinical efficacy and safety endpoints consistently achieved across multiple Phase 2 studies Phase 2b/3 Saturn-1 enrollment complete w
Slide 28: © Tarsus Pharmaceuticals 2021
© Tarsus Pharmaceuticals 2021
Tarsus Pharmaceuticals — Investor Presentation (April 2021) on 6ix